* AVITA Medical Inc RCEL.OQ RCEL.O is expected to show a
rise
in quarterly revenue when it reports results on May 11.
* The Valencia California California-based company is
expected to
report a 37.0% increase in revenue to $10.331 million from
$7.54 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for AVITA Medical Inc
is for
a loss of 25 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AVITA
Medical Inc
is $17.5, above its last closing price of $15.25.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.28 -0.29 -0.22 Beat 24.7
Sep. 30 2022 -0.34 -0.34 -0.22 Beat 35.2
Jun. 30 2022 -0.38 -0.39 -0.25 Beat 35.9
Mar. 31 2022 -0.39 -0.38 -0.38 Met 0
-0.34
This summary was machine generated May 10 at 02:01 GMT. All
figures in US dollars unless otherwise stated